NCT05395052 2023-09-21FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid TumorsFate TherapeuticsPhase 1 Terminated5 enrolled
NCT04464967 2021-05-12Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR CancersNKGen Biotech, Inc.Phase 1/2 Withdrawn
NCT00622674 2017-12-02Bortezomib and Cetuximab in Treating Patients With Advanced Solid TumorsMasonic Cancer Center, University of MinnesotaPhase 1 Completed37 enrolled